Skip to main content

Table 2 Adverse events

From: Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial

 

Safety/ITT population

 

ABvac40 (n = 16)

Placebo (n = 8)

Total (N = 24)

 

AEs (n)

No. of patients (%)

AEs (n)

No. of patients (%)

AEs (n)

No. of patients (%)

p Value

Total AEs

42

11 (69%)

29

7 (88%)

71

18 (75%)

0.6214

 Neurological

9

5 (31%)

6

5 (63%)

15

10 (42%)

0.2038

 Psychiatric

2

2 (13%)

1

1 (13%)

3

3 (13%)

1.0000

 Cardiovascular

1

1 (6%)

1

1 (13%)

2

2 (8%)

1.0000

  1. AE Adverse event, ITT Intention to treat
  2. Analysis was done using Fisher’s exact test. See Additional file 3: Table S1 for a complete list of reported AEs